ST Pharm Co Ltd
KOSDAQ:237690
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60 400
117 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
ST Pharm Co Ltd
Cash & Cash Equivalents
ST Pharm Co Ltd
Cash & Cash Equivalents Peer Comparison
207940
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Cash & Cash Equivalents
₩50.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Cash & Cash Equivalents
₩973.5B
|
CAGR 3-Years
129%
|
CAGR 5-Years
147%
|
CAGR 10-Years
N/A
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Cash & Cash Equivalents
₩5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Cash & Cash Equivalents
₩15.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
18%
|
CAGR 10-Years
51%
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Cash & Cash Equivalents
₩589.8m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
E
|
ENCell Co Ltd
KOSDAQ:456070
|
Cash & Cash Equivalents
₩18.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ST Pharm Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
50.1B
KRW
Based on the financial report for Jun 30, 2024, ST Pharm Co Ltd's Cash & Cash Equivalents amounts to 50.1B KRW.
What is ST Pharm Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
26%
Over the last year, the Cash & Cash Equivalents growth was 46%. The average annual Cash & Cash Equivalents growth rates for ST Pharm Co Ltd have been 22% over the past three years , 26% over the past five years .
You don't have any saved screeners yet
